Status:
UNKNOWN
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Lead Sponsor:
Tianjin Third Central Hospital
Collaborating Sponsors:
BGI, China
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis an...
Detailed Description
Hepatocellular Carcinoma (HCC)is one of the cancers with high morbidity and mortality in the world , and the incidence of liver cancer in China is particularly serious. In 2020, there will be 410,000 ...
Eligibility Criteria
Inclusion
- Patients diagnosed as chronic liver disease, including but not limited to chronic hepatitis B, chronic hepatitis C, fatty liver;
- Intrahepatic nodules detectable by ultrasound;
- Unlimited number of nodules;
- The patient has signed an informed consent form.
Exclusion
- Previously diagnosed malignant tumors；
- Patients who are unable to cooperate with venous blood sampling；
- According to the judgment of the investigator, the participants are not suitable to participate in this study.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06134973
Start Date
September 1 2023
End Date
June 1 2025
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
王芳
Tianjin, Tianjin Municipality, China, 300170